Rein Therapeutics Inc (RNTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.80 (+1.37%), Market cap $0.09B, 52-week low–high $0.97 ~ $2.05.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium
Financial statements, price targets, institutional (13F) holdings and related news for Rein Therapeutics Inc are updated in real time on BlackAll Trade.
Rein Therapeutics Inc trades at $0.80 (+1.37%). Real-time quotes and charts are available on BlackAll Trade.
Rein Therapeutics Inc has a market cap of about $0.09B.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lea